Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Oncology Briefings™: Best Practices for the Management of CML Across Lines of Care

Release Date: July 31, 2020
Expiration Date: July 31, 2021

Activity Overview

This online activity is designed to provide a concise and focused overview on the efficacy and safety of currently available and emerging therapies for patients with newly-diagnosed CML and those with CML resistant or intolerant to frontline TKIs. The engaging, multimedia format of this program includes audio commentary from an expert thought leader, integrated with text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational initiative is directed toward medical oncologists and hematologists who treat patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment of hematologic malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify factors that influence treatment selection and discontinuation in patients with CML
  • Discuss existing and emerging novel therapies and combination strategies across treatment of patients with CML
  • Apply evidence-based recommendations for ensuring adherence to current TKI therapies and managing treatment-related toxicities

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Jorge Cortes, MD
Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta University
Augusta, GA

Disclosures: Grant Research Support (to my institution): Bristol Myers Squibb, Novartis, Pfizer, Takeda, Sun Pharma; Consultant for Novartis, Pfizer, Takeda

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant as a substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By